Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

Published:2021-04 Issue:2 Volume:6 Page:100043
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Ledermann J.A.,Embleton-Thirsk A.C.,Perren T.J.,Jayson G.C.,Rustin G.J.S.,Kaye S.B.,Hirte H.,Oza A.,Vaughan M.,Friedlander M.,González-Martín A.,Deane E.,Popoola B.,Farrelly L.,Swart A.M.,Kaplan R.S.,Parmar M.K.B.

Funder

Cancer Research UK

Cancer Australia

Canadian Cancer Society

AstraZeneca

Medical Research Council

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Ovarian cancer;Jayson;Lancet,2014

2. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis;Hicklin;J Clin Oncol,2005

3. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N Engl J Med,2011

4. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J Clin Oncol,2012

5. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial;Pujade-Lauraine;J Clin Oncol,2014

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I open-label study of cediranib plus etoposide and cisplatin as first-line therapy for patients with extensive-stage small-cell lung cancer or metastatic neuroendocrine non-small-cell lung cancer;Clinical Lung Cancer;2024-09

2. Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review;Future Oncology;2024-08-12

3. Ovarian cancer: Diagnosis and treatment strategies (Review);Oncology Letters;2024-07-18

4. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review;Frontiers in Pharmacology;2024-06-14

5. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials;Frontiers in Pharmacology;2024-05-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3